Metastatic Prostate Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Metastatic Prostate Cancer – Drugs In Development, 2023’, provides an overview of the Metastatic Prostate Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Prostate Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
- The report reviews pipeline therapeutics for Metastatic Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Prostate Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Prostate Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abion IncActinium Pharmaceuticals Inc
Advanced Accelerator Applications SA
Alligator Bioscience AB
Alphamab Oncology
Antev Ltd
Artelo Biosciences Inc
Beth Israel Deaconess Medical Center
Bio-Thera Solutions Ltd
BioNTech SE
Bristol-Myers Squibb Co
Camurus AB
Cancer Targeted Technology LLC
Crystal Nucleus Biomedical Technology (Nanjing) Co Ltd
CSPC Pharmaceutical Group Ltd
CureMeta LLC
EpimAb Biotherapeutics Inc
Exelixis Inc
For-Robin Inc
Foresee Pharmaceuticals Co Ltd
Fusion Pharmaceuticals Inc
Glycomantra Inc
GlyTherix Ltd
GSK plc
Huabo Biopharm (Shanghai) Co Ltd
Immune Pharmaceuticals Inc
Immunogenesis Inc
Immunova Therapeutics Inc
Kintor Pharmaceutical Ltd
Komipharm International Co Ltd
Kyorin University
Livzon Pharmaceutical Group Co Ltd
Lotus Pharmaceutical Co Ltd
Luye Pharma Group Ltd
Memorial Sloan Kettering Cancer Center
MetasTx LLC
Nanjing Medical University Hospital
National Cancer Institute US
NeoTX Therapeutics Ltd
Novartis AG
Oncotelic Therapeutics Inc
Oncternal Therapeutics
Oneness Biotech Co Ltd
Orion Corp
Pharmadrug Inc
Praesidia Biotherapeutics Inc
Precision Molecular Inc
QSAM Therapeutics Inc
Ratio Therapeutics Inc
Roswell Park Cancer Institute
Samyang Biopharmaceuticals Corp
Sathgen Biotech
Shanghai Yuyao Biotechnology Ltd
Shanxi Kangbao Biological Product Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Spanish National Research Council
Spexis AG
SynDevRx Inc
Telix Pharmaceuticals Ltd
Theratechnologies Inc
University of East Anglia
Wuxi Biocity Biopharma Co Ltd
Xennials Therapeutics Inc